Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer

Choong Kun Lee, Myung Eun Lee, Won Suk Lee, Jeong Min Kim, Kyu Hyun Park, Tae Soo Kim, Kang Young Lee, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticle

11 Citations (Scopus)

Fingerprint Dive into the research topics of 'Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences